Emory University

Running trials

• Not yet recruiting

  Kidney RISE: Randomized Integrated Supportive CarE Trial

  NCT07741357· NYU Langone Health· Source

• Not yet recruiting

  Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta

  NCT07535346· Emory University· Source

• Not yet recruiting

  Topical Curcumin for HPV Related Cervical Disease

  NCT04266275· Phase 2· Lisa Flowers· Source

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Electrophysiologic Mechanisms of Ketamine Antidepressant Response

  NCT07768618· Phase 2· Emory University· Source

• Recruiting

  Thrive With Type 1 Diabetes 2026

  NCT07522866· Emory University· Source

• Recruiting

  A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

  NCT07778667· Phase 3· Idorsia Pharmaceuticals Ltd.· Source

• Not yet recruiting

  Hypoxic Red Blood Cells in Sickle Cell Anemia

  NCT06743113· Hemanext· Source

• Not yet recruiting

  Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

  NCT07778602· Early phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Johns Hopkins University· Source

• Recruiting

  A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

  NCT07459634· Phase 2· Jazz Pharmaceuticals· Source

• Not yet recruiting

  Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease

  NCT07675408· Fortis Medical Devices Limited· Source

• Enrolling by invitation

  Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort

  NCT07858214· Head Diagnostics· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Not yet recruiting

  Handgrip Exercise Training and CKD

  NCT07094906· Emory University· Source

• Not yet recruiting

  H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

  NCT07484139· Phase 2· UNC Lineberger Comprehensive Cancer Center· Source

• Recruiting

  Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

  NCT07569926· Phase 4· Blue Earth Diagnostics· Source

• Recruiting

  An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· Phase 2· Yale University· Source

• Enrolling by invitation

  Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV

  NCT07461350· University of California, San Francisco· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

  NCT07324031· AtaCor Medical, Inc.· Source

• Not yet recruiting

  Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program

  NCT07623759· Emory University· Source

• Not yet recruiting

  An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

  NCT07613398· Matthias Stuber· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

  NCT07579702· Insulet Corporation· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Horizon Two: HR NDMM (MMRC-100)

  NCT07053436· Phase 2· Multiple Myeloma Research Consortium· Source

• Recruiting

  Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

  NCT07103746· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Recruiting

  A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study

  NCT07525843· Carelon Research· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Indiana University· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

  NCT07379827· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

  NCT07228117· Medtronic MiniMed, Inc.· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· Phase 1· Johnson & Johnson Enterprise Innovation Inc.· Source

• Recruiting

  A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

  NCT07187973· Phase 1· Disc Medicine, Inc· Source

• Recruiting

  Tofersen in Non-SOD1 ALS

  NCT07294144· Phase 2· Washington University School of Medicine· Source

• Recruiting

  Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  NCT07288359· Phase 1/2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

  NCT07296484· Phase 2· Sparrow Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Pfizer· Source

• Recruiting

  BoxX-NoAF Clinical Trial

  NCT06989775· AtriCure, Inc.· Source

• Recruiting

  Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

  NCT07143669· Blueprint Medicines Corporation· Source

Showing 50 of 316.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer10 recruiting
• Lung cancer9 recruiting
• Parkinson disease9 recruiting
• Bladder cancer8 recruiting
• Childhood cancers7 recruiting
• Colorectal cancer7 recruiting
• Head and neck cancer7 recruiting
• Coronary artery disease6 recruiting
• Multiple myeloma6 recruiting
• Type 1 diabetes6 recruiting
• ALS (motor neurone disease)5 recruiting
• Alzheimer disease5 recruiting
• Chronic kidney disease5 recruiting
• Crohn's disease5 recruiting
• Lupus (SLE)5 recruiting
• Stroke5 recruiting
• Acute myeloid leukaemia4 recruiting
• Atrial fibrillation4 recruiting
• Depression4 recruiting
• Gastric and oesophageal cancer4 recruiting
• HIV4 recruiting
• Myelodysplastic syndromes4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Pancreatic cancer4 recruiting
• Sickle cell disease4 recruiting
• Type 2 diabetes4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Aortic stenosis3 recruiting
• Cervical cancer3 recruiting
• Congenital heart disease3 recruiting
• Cystic fibrosis3 recruiting
• Fabry disease3 recruiting
• Glioblastoma3 recruiting
• High blood pressure3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Melanoma3 recruiting
• Metastatic breast cancer3 recruiting
• Ovarian cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Amyloidosis2 recruiting
• Aortic aneurysm2 recruiting
• Autism2 recruiting
• Endometrial cancer2 recruiting
• Frontotemporal dementia2 recruiting
• Heart failure2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Lewy body dementia2 recruiting
• Multiple sclerosis2 recruiting
• Multiple system atrophy2 recruiting
• Osteoporosis2 recruiting
• Pompe disease2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Ulcerative colitis2 recruiting
• ANCA-associated vasculitis1 recruiting
• Brain aneurysm1 recruiting
• Bronchiectasis1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Cushing's syndrome1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Dystonia1 recruiting
• Epilepsy1 recruiting
• Essential tremor1 recruiting
• Graves' disease and hyperthyroidism1 recruiting
• Long COVID and ME/CFS1 recruiting
• Macular degeneration1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoarthritis1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Postural tachycardia syndrome (POTS)1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Schizophrenia1 recruiting
• Spinal cord injury1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  Simplified Onboarding in Adults With Type 2 Diabetes

  NCT07070830· Insulet Corporation· Source

• Terminated

  VIZ ACCESS HCM - Multi-Site Registry

  NCT07103057· Viz.ai, Inc.· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Terminated

  Study of the Oral Treatment MTR-601 in Cervical Dystonia

  NCT06830642· Phase 2· Motric Bio· Source

• Completed

  A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

  NCT06118515· Phase 1· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

  NCT06791122· Boehringer Ingelheim· Source

• Terminated

  Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

  NCT06042257· Phase 2· Rachel G. Greenberg, MD, MB, MHS· Source

• Withdrawn

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Phase 3· Vanderbilt University Medical Center· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Completed

  Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

  NCT04677777· Phase 1· Prolong Pharmaceuticals· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source

• Completed

  Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes

  NCT06127251· Emory University· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Improving Sleep and AD Biomarkers

  NCT06029894· Emory University· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

  NCT06019728· Phase 4· Sanofi· Source

• Completed

  Web-based Physical Activity Intervention to Promote Physical Activity

  NCT05803304· Emory University· Source

• Completed

  HEAL-LAA Clinical Trial

  NCT05809596· Boston Scientific Corporation· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Ferring Pharmaceuticals· Source

• Completed

  Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening

  NCT06561217· University of Pennsylvania· Source

• Recruiting

  Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

  NCT05836259· Phase 1/2· Tenaya Therapeutics· Source

• Terminated

  Achieving Portal Access With Scorpion Post-Approval Study (APASS)

  NCT05765253· Argon Medical Devices· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Tandem Diabetes Care, Inc.· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Hoffmann-La Roche· Source

• Terminated

  Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care

  NCT05456139· Florida State University· Source

• Completed

  NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

  NCT05666713· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· COMPASS Pathways· Source

• Completed

  ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

  NCT05653271· Phase 1· Acepodia Biotech, Inc.· Source

• Terminated

  Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

  NCT05068726· GE Healthcare· Source

• Completed

  Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

  NCT05660772· Phase 3· Lipogems International spa· Source

• Terminated

  Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

  NCT05306873· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes

  NCT05644730· Ideal Medical Technologies· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Sumitomo Pharma America, Inc.· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Engrail Therapeutics INC· Source

• Completed

  Improving Sleep and Cognition in Alzheimer's Disease

  NCT05200208· Emory University· Source

• Completed

  Pharmacy-based Pre-exposure Prophylaxis

  NCT04393935· Emory University· Source

• Completed

  Efficacy in iNPH Shunting (PENS) Trial

  NCT05081128· Johns Hopkins University· Source

• Completed

  A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  NCT05347485· Phase 2· Janssen Scientific Affairs, LLC· Source

• Completed

  Time in Glucose Hospital Target

  NCT05135676· Jaeb Center for Health Research· Source

• Withdrawn

  Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

  NCT05204160· Phase 2· Emory University· Source

• Terminated

  Prevention of NAFLD in Hispanic Children

  NCT05292352· Emory University· Source

• Completed

  A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

  NCT05241834· Phase 1· Eli Lilly and Company· Source

• Completed

  Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy

  NCT04997109· Emory University· Source

• Completed

  Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

  NCT05276349· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Completed

  Achieving Portal Access With Scorpion Post-Approval Study 2

  NCT06856655· Argon Medical Devices· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain

  NCT04906447· Phase 2· University of Illinois Chicago· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Vivoryon Therapeutics N.V.· Source

Showing 50 of 146.

Conditions

Diseases this institution publishes on or runs trials for.

• HIV479 works · 18 trials
• Stroke409 works · 16 trials
• Alzheimer disease339 works · 20 trials
• Obesity232 works · 6 trials
• Heart failure225 works · 17 trials
• Type 2 diabetes169 works · 12 trials
• Lung cancer151 works · 27 trials
• Prostate cancer136 works · 15 trials
• Tuberculosis117 works · 0 trials
• Schizophrenia111 works · 2 trials
• Atrial fibrillation109 works · 8 trials
• Cystic fibrosis107 works · 9 trials
• Parkinson disease101 works · 13 trials
• Chronic kidney disease101 works · 12 trials
• Sickle cell disease96 works · 12 trials
• Epilepsy90 works · 5 trials
• Coronary artery disease87 works · 16 trials
• Multiple myeloma78 works · 25 trials
• Melanoma74 works · 7 trials
• Liver and biliary tract cancer73 works · 3 trials
• Asthma71 works · 2 trials
• Kidney cancer65 works · 6 trials
• Childhood cancers65 works · 20 trials
• Colorectal cancer58 works · 16 trials
• Triple-negative breast cancer54 works · 7 trials
• Congenital heart disease53 works · 4 trials
• Autism49 works · 3 trials
• Head and neck cancer48 works · 14 trials
• Ovarian cancer48 works · 7 trials
• Cervical cancer47 works · 6 trials